CD8A and neoplasm: As Tregs are most sensitive to BAY1082439, intermittent dosing is sufficient to reduce tumor-associated Treg number and alleviate its immunosuppressive activity, which provides a window for CD8+ T cell activation and clonal expansion, as indicated by RNA-seq analysis of isolated CD8+ T cells (Figs. 4 and 7).